Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Most cancers

Sacituzumab tirumotecan (sac-TMT) led to a 51% discount within the danger of development or dying in contrast with chemotherapy in sufferers with nonsquamous epidermal development issue receptor–mutated non–small cell lung most cancers that developed epidermal development issue receptor tyrosine kinase inhibitor resistance, in accordance with part 3 outcomes of the OptiTROP-Lung04 research offered throughout the 2025 ESMO Congress.

Outcomes confirmed that, at a median follow-up of 18.9 months, the median progression-free survival assessed by blinded impartial central assessment was 8.3 months with sac-TMT and 4.3 months with chemotherapy. The 12-month progression-free survival charges had been 32% and eight%, respectively. The profit with sac-TMT was noticed throughout all prespecified subgroups.

The investigator-assessed median progression-free survival was 8.4 months with sac-TMT and 4.8 months with chemotherapy. The 12-month charges had been 35% and 11%, respectively.

“sac-TMT demonstrated statistically important and clinically significant enhancements in progression-free and total survival in comparison with platinum-based chemotherapy,” lead research creator Dr. Li Zhang, professor of medical oncology at Solar Yat-sen College Most cancers Middle in Guangzhou, China, stated in an oral presentation of the info. “The outcomes of the OptiTROP-Lung04 research help sac-TMT as a promising new therapy possibility for sufferers with EGFR-mutated non–small cell lung most cancers with epidermal development issue receptor tyrosine kinase inhibitor resistance.”

Sac-TMT is a TROP2 antibody-drug conjugate with a singular biofunctional linker that maximizes supply of a belotecan-derivative topoisomerase I inhibitor payload to tumor cells. TROP2 is very expressed in sufferers with EGFR-mutated non–small cell lung most cancers, and preclinical knowledge have proven that sac-TMT internalization and uptake are enhanced by EGFR mutations.

Present customary choices for sufferers who relapse on third-generation EGFR tyrosine kinase inhibitors stay platinum-based chemotherapy, however extra choices are wanted.

Within the multicenter, open-label, part 3 OptiTROP-Lung04 trial, 376 sufferers with nonsquamous stage 3B/3C or 4 non–small cell lung most cancers with EGFR-sensitive mutations had been randomly assigned 1:1 to obtain sac-TMT at 5 milligrams per kilogram intravenously each two weeks or Alimta at 500 milligrams per sq. meter plus carboplatin space below the curve 5 or cisplatin at 75 milligrams per sq. meter each three weeks for as much as 4 cycles, adopted by Alimta upkeep at 500 milligrams per sq. meter each three weeks. Therapy was given till illness development, insupportable toxicity, or affected person request to discontinue remedy.

To be eligible for enrollment, sufferers wanted to have an Japanese Cooperative Oncology Group efficiency standing of zero or one and development after third-generation tyrosine kinase inhibitor remedy or development after first- or second-generation tyrosine kinase inhibitors with T790M-negative mutations.

Stratification components included prior EGFR tyrosine kinase inhibitor remedy (third-generation in frontline versus second line versus no third-generation) or mind metastases (sure versus no).

The first finish level was progression-free survival assessed by blinded impartial central assessment; secondary finish factors had been total survival, investigator-assessed progression-free survival, goal response fee, illness management fee, length of response, and security.

A complete 148 sufferers on sac-TMT discontinued therapy because of illness development (125 sufferers), affected person or guardian withdrawal (12 sufferers), dying (6 sufferers), negative effects (2 sufferers), or different (3 sufferers). Within the chemotherapy arm, 179 sufferers discontinued therapy because of illness development (140 sufferers), affected person/guardian withdrawal (16 sufferers), dying (9 sufferers), negative effects (5 sufferers), protocol deviation (2 sufferers), or different (7 sufferers). A complete 69 and 102 sufferers in every arm, respectively, discontinued from the research because of dying (67 and 101 sufferers) or had been misplaced to follow-up (2 and 1 sufferers).

Affected person baseline traits had been usually properly balanced between the sac-TMT (188 sufferers) and chemotherapy arms (188 sufferers). The median age was 60 years and 59 years, and 31% and 27% had been at the least 65 years. Most had a efficiency standing of 1 (81% and 77%), had no smoking historical past (77% and 72%), had stage 4 illness (97% and 98%), and at the least three metastatic websites (68% and 67%). A complete 18% and 19% had mind metastases, and 13% and 18% had liver metastases. The bulk in every arm had exon 19 deletions (56% and 63%), had unknown T790M mutation standing (59% and 60%), and acquired a previous third-generation EGFR tyrosine kinase inhibitor within the frontline setting (63% and 62%).

The interim evaluation confirmed that for sac-TMT, the median total survival was not reached in contrast with 17.4 months with chemotherapy, resulting in a 40% discount within the danger of dying. The 18-month total survival charges had been 66% and 48%, respectively. General survival was improved with sac-TMT throughout all prespecified subgroups.

Dr. Zhang additionally reported on subsequent anticancer therapy from the trial; 72% of sufferers on sac-TMT and 86% of these on chemotherapy acquired at the least one subsequent therapy. Within the sac-TMT and chemotherapy teams, respectively, these included chemotherapy (42%; 54%), particularly Alimta-based chemotherapy (37%; 13%), an EGFR tyrosine kinase inhibitor (43%; 40%), an anti-angiogenic agent (35%; 48%), immunotherapy (17%; 25%), or an antibody-drug conjugate (1%; 20%).

When assessed by way of blinded impartial central assessment, the target response fee with sac-TMT was 61% in contrast with 43% with chemotherapy; the illness management fee was 87% and 80%, respectively. The median length of response was 8.3 months with sac-TMT and 4.2 months with chemotherapy; the 12-month charges had been 36% versus 8%, respectively.

Concerning security, treatment-related negative effects occurred in 100% and 98% of sac-TMT– and chemotherapy-treated sufferers, respectively. Grade 3 or larger negative effects occurred in 58% and 54% of sufferers, and critical negative effects occurred in 9% and 18% of sufferers, respectively. Uncomfortable side effects that led to dose reductions and interruptions occurred in 30% and 37% of sufferers on sac-TMT; there have been no negative effects that led to discontinuation or dying. Within the chemotherapy arm, these charges had been 23% and 33%; one affected person every skilled negative effects resulting in discontinuation or dying.

The median length of publicity was 9.6 months with sac-TMT and 4.9 months with chemotherapy. The most typical negative effects in each arms had been hematologic; sac-TMT had larger incidence of stomatitis that had been principally grade 1 or 2 (any-grade 62%; grade ≥3 5%). Ocular floor toxicities additionally occurred in 10% of sufferers on sac-TMT, all grade 1 or 2. No instances of interstitial lung illness or pneumonitis had been reported on the sac-TMT arm.

Part 3 trials are at the moment exploring sac-TMT alone and together with Tagrisso in sufferers with EGFR-mutant non–small cell lung most cancers.

References

1. “Sacituzumab tirumotecan versus platinum-based chemotherapy in EGFR-mutated non-small cell lung most cancers following development on EGFR-TKIs” by Dr. Zhang, et al., offered on the 2025 ESMO Congress.
2. “Sacituzumab tirumotecan in superior non-small-cell lung most cancers with or with out EGFR mutations” by Dr. Zhao, et al., Nat Med.

For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.